Health Care [ 10/12 ] | Biotechnology [ 54/74 ]
NASDAQ | Common Stock
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders.
It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.
It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders.
The company was founded in 2018 and is based in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 3, 24 | -0.20 Decreased by -33.33% | -0.23 Increased by +13.04% |
| May 3, 24 | -0.15 Increased by +28.57% | -0.22 Increased by +31.82% |
| Feb 29, 24 | -0.21 Increased by +34.38% | -0.20 Decreased by -5.00% |
| Nov 9, 23 | -0.11 Decreased by -1.00 K% | -0.20 Increased by +45.00% |
| Aug 23, 23 | -0.15 Decreased by -1.60 K% | -0.25 Increased by +40.00% |
| May 11, 23 | -0.21 Decreased by -90.91% | -0.22 Increased by +4.55% |
| Mar 2, 23 | -0.32 Decreased by -255.56% | -0.17 Decreased by -88.24% |
| Nov 10, 22 | -0.01 Increased by +75.00% | -0.16 Increased by +93.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 80.00 K Increased by +N/A% | -7.67 M Increased by +36.69% | Decreased by -9.58 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -11.27 M Increased by +32.95% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.65 M Decreased by -198.35% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.73 M Decreased by -204.19% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.11 M Decreased by -244.01% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -16.81 M Decreased by -310.93% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | 5.74 M Increased by +412.68% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | 7.42 M Increased by +449.08% | Increased by +N/A% Decreased by N/A% |